KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Debt: 2017-2019

Historic Non-Current Debt for Xenon Pharmaceuticals (XENE) over the last 2 years, with Dec 2019 value amounting to $10.9 million.

  • Xenon Pharmaceuticals' Non-Current Debt was N/A to $10.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was $10.9 million, marking a year-over-year change of. This contributed to the annual value of $10.9 million for FY2019, which is N/A change from last year.
  • As of Q4 2019, Xenon Pharmaceuticals' Non-Current Debt stood at $10.9 million, which was down 7.61% from $11.8 million recorded in Q3 2019.
  • In the past 5 years, Xenon Pharmaceuticals' Non-Current Debt ranged from a high of $15.1 million in Q1 2019 and a low of $5.5 million during Q1 2018.
  • For the 3-year period, Xenon Pharmaceuticals' Non-Current Debt averaged around $11.2 million, with its median value being $11.8 million (2018).
  • Over the last 5 years, Xenon Pharmaceuticals' Non-Current Debt had its largest YoY gain of 176.46% in 2019, and its largest YoY loss of 20.82% in 2019.
  • Xenon Pharmaceuticals' Non-Current Debt (Quarterly) stood at $6.1 million in 2017, then reached $14.9 million in 2018, then decreased by 20.82% to $10.9 million in 2019.
  • Its Non-Current Debt was $10.9 million in Q4 2019, compared to $11.8 million in Q3 2019 and $13.2 million in Q2 2019.